AJTMH Tropical Medicine and Hygiene News
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am. J. Trop. Med. Hyg., 75(4), 2006, pp. 659-663
Copyright © 2006 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by REID, M.
Right arrow Articles by MONATH, T. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by REID, M.
Right arrow Articles by MONATH, T. P.
Related Collections
Right arrow Mosquitoes
Right arrow Yellow Fever
Right arrow Vaccine

EXPERIMENTAL INFECTION OF CULEX ANNULIROSTRIS, CULEX GELIDUS, AND AEDES VIGILAX WITH A YELLOW FEVER/JAPANESE ENCEPHALITIS VIRUS VACCINE CHIMERA (CHIMERIVAXTM-JE)

MARK REID*, DONNA MACKENZIE, ANDREW BARON, NATALIE LEHMANN, KYM LOWRY, JOHN AASKOV, FARSHAD GUIRAKHOO, AND THOMAS P. MONATH
Australian Army Malaria Institute, Brisbane, Queensland, Australia; School of Life Sciences, Queensland University of Technology, Brisbane, Queensland, Australia; Acambis Inc., Cambridge, Massachusetts

Australian mosquitoes from which Japanese encephalitis virus (JEV) has been recovered (Culex annulirostris, Culex gelidus, and Aedes vigilax) were assessed for their ability to be infected with the ChimeriVaxTM-JE vaccine, with yellow fever vaccine virus 17D (YF 17D) from which the backbone of ChimeriVaxTM-JE vaccine is derived and with JEV-Nakayama. None of the mosquitoes became infected after being fed orally with 6.1 log10 plaque-forming units (PFU)/mL of ChimeriVaxTM-JE vaccine, which is greater than the peak viremia in vaccinees (mean peak viremia = 4.8 PFU/mL, range = 0–30 PFU/mL of 0.9 days mean duration, range = 0–11 days). Some members of all three species of mosquito became infected when fed on JEV-Nakayama, but only Ae. vigilax was infected when fed on YF 17D. The results suggest that none of these three species of mosquito are likely to set up secondary cycles of transmission of ChimeriVaxTM-JE in Australia after feeding on a viremic vaccinee.


Received March 27, 2006. Accepted for publication June 4, 2006.

Acknowledgments: We thank Cassie Jansen and Dr. Andrew van den Hurk (Queensland Health Pathology and Scientific Services, Brisbane, Queensland, Australia), and Corporal Raethea Huggins, Lieutenant Robert Marlow, Major Steven Frances, and Lieutenant Colonel Robert Cooper (Australian Army) for entomologic assistance and technical advice. We also thank Helen Gramatonev (statistical consultant) for statistical support.

Financial support: This study was supported by Acambis Inc. (Cambridge, MA) and the Joint Health Support Agency, Defence Health Services (Canberra, Australia).

Disclosure: Mark Reid has acted as a paid consultant to Acambis Inc. in relation to JE vaccine trials. Farshad Guirakhoo and Thomas P. Monath are current and former employees of Acambis Inc. These statements are made in the interest of full disclosure and not because the authors consider this to be a conflict of interest.

Disclaimer: All investigations were approved by the Office of the Gene Technology Regulator and the Australian Quarantine Inspection Service (Canberra, Australia). The use of mice (for mosquito colony maintenance) was approved by the Animal Experimentation and Ethics Committee of the Australian Army Malaria Institute in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, Version 7. The opinions expressed herein are those of the authors and do not necessarily reflect those of the Australian Defence Health Services or any extant policy.

* Address correspondence to Mark Reid, Australian Army Malaria Institute, Weary Dunlop Drive, Gallipoli Barracks, Enoggera, Queensland 4051, Australia. E-mail: markreid2{at}optusnet.com.au

Authors’ addresses: Mark Reid, Donna MacKenzie, Andrew Baron, and Natalie Lehmann, Australian Army Malaria Institute, Weary Dunlop Drive, Gallipoli Barracks, Enoggera, Queensland, 4051 Australia. Kym Lowry and John Aaskov, Australian Army Malaria Institute, Weary Dunlop Drive, Gallipoli Barracks, Enoggera, Queensland, 4051 Australia and School of Life Sciences, Queensland University of Technology, GPO Box 2434, Brisbane, Queensland, 4001 Australia. Farshad Guirakhoo, Acambis Inc., 38 Sidney Street, Cambridge MA 02139. Thomas P. Monath, Kleiner Perkins Caulfield & Byers, 21 Finn Rd., Harvard, MA 01451.




This article has been cited by other articles:


Home page
Am J Trop Med HygHome page
N. C. Arrigo, D. M. Watts, I. Frolov, and S. C. Weaver
Experimental Infection of Aedes sollicitans and Aedes taeniorhynchus with Two Chimeric Sindbis/Eastern Equine Encephalitis Virus Vaccine Candidates
Am J Trop Med Hyg, January 1, 2008; 78(1): 93 - 97.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society of Tropical Medicine and Hygiene.